Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 3:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1129–1152 of 13,615 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Dermatologic Disorders Clear all
Completed Phase 4 Interventional Accepts healthy volunteers

Aldara for the Treatment of Extensive Alopecia Areata

NCT00177021
View directory record Official record
Conditions
Alopecia Areata
Interventions
Aldara Cream 5%
Drug
Lead sponsor
Hordinsky, Maria K., MD
Individual
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2002
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 13, 2006 · Synced Oct 31, 2026, 3:23 PM EDT
Completed No phase listed Observational

Utilizing Continuous Glucose Monitoring to Characterize and Manage Hyperglycemia in Patients Initiating Alpelisib

NCT06083038
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Alpelisib, FreeStyle Libre 2 Continuous Glucose Monitor
Drug · Device
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years and older
Enrollment
8 participants
Timeline
2023 – 2026
U.S. locations
1
States / cities
Saint Louis Park, Minnesota
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 31, 2026, 3:23 PM EDT
Active, not recruiting Phase 3 Interventional

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

NCT06500455
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Digestive System Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Computed Tomography, Fractionated Stereotactic Radiation Therapy, Magnetic Resonance Imaging, Stereotactic Radiosurgery
Procedure · Radiation
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
262
States / cities
Tucson, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 189 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 31, 2026, 3:23 PM EDT
Completed Phase 3 Interventional Results available

Acyclovir in Preventing Herpes Simplex Virus Infection in Patients With Neutropenia

NCT00855309
View directory record Official record
Conditions
Herpes Simplex
Interventions
acyclovir sodium
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 6, 2018 · Synced Oct 31, 2026, 3:23 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Imaging Lymphatic Function in Normal Subjects and in Persons With Lymphatic Disorders

NCT00833599
View directory record Official record
Conditions
Lymphedema, Lymphatic Disorders, Lipedema, Vascular Malformation, Vascular Anomaly, Dercum Disease
Interventions
NIRFLI with ICG
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
3 Months and older
Enrollment
283 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2030
U.S. locations
3
States / cities
Houston, Texas • The Woodlands, Texas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 31, 2026, 3:23 PM EDT
Not yet recruiting Not applicable Interventional

Fit2ThriveMB: Optimization of a Physical Activity Promotion Intervention for Metastatic Breast Cancer Patients

NCT07840599
View directory record Official record
Conditions
Metastatic Breast Cancer, Metastatic Breast Cancer (MBC), Metastatic Breastcancer
Interventions
Core Intervention, EHR Integration (On v. Off), Weekly Coaching, Social+ (on v. off), Static Goal Setting, Bi-Weekly Coaching, Highly Tailored Goal Setting
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 31, 2026, 3:23 PM EDT
Completed Not applicable Interventional

Sun Protection of Kidney Transplant Recipients

NCT01646099
View directory record Official record
Conditions
Unspecified Complication of Kidney Transplant, Disorder Related to Renal Transplantation
Interventions
Internet-based sun protection education
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 85 Years
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 23, 2015 · Synced Oct 31, 2026, 3:23 PM EDT
Completed No phase listed Observational

A Study of Real-World Treatment Patterns and Outcomes Among HR+/HER2- Metastatic Breast Cancer Patients Treated With First-Line CDK4/6 Inhibitors

NCT07512063
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 31, 2026, 3:23 PM EDT
Recruiting Phase 1Phase 2 Interventional

Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders

NCT06434363
View directory record Official record
Conditions
Autoimmune Disorders, Systemic Sclerosis, Systemic Lupus Erythematosus, Lupus, Lupus Nephritis
Interventions
Tafasitamab, Fludarabine phosphate, Cyclophosphamide, Tafasitamab and NK cells
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 31, 2026, 3:23 PM EDT
Active, not recruiting Not applicable Interventional

Post Market Clinical Follow-up (PMCF) Study of the A.L.P.S. Proximal Humerus Plating System

NCT03626038
View directory record Official record
Conditions
Osteoarthritis, Rheumatoid Arthritis, Post-Traumatic Arthritis, Psoriatic Arthritis, Proximal Humeral Fracture
Interventions
A.L.P.S. Proximal Humerus Plating System
Device
Lead sponsor
Zimmer Biomet
Industry
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 31, 2026, 3:23 PM EDT
Completed Phase 1 Interventional

A Pilot Trial of Tamoxifen and 4-HPR (4-N-Hydroxyphenyl Retinamide) in Persons at High Risk for Developing Breast Cancer

NCT00001378
View directory record Official record
Conditions
Breast Cancer, Breast Neoplasms
Interventions
fenretinide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1994 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 31, 2026, 3:23 PM EDT
Terminated Phase 2 Interventional Results available

Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer

NCT04958785
View directory record Official record
Conditions
Triple-Negative Breast Cancer
Interventions
Magrolimab, Nab-Paclitaxel, Paclitaxel, Sacituzumab Govitecan-hziy
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
19
States / cities
Phoenix, Arizona • Fresno, California • Fullerton, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 31, 2026, 3:23 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of Debio 1347 Plus Fulvestrant in Patients With Metastatic Breast Cancer

NCT03344536
View directory record Official record
Conditions
Breast Cancer
Interventions
Fulvestrant, Debio 1347
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 25, 2022 · Synced Oct 31, 2026, 3:23 PM EDT
Completed Not applicable Interventional Results available

Individualized vs. Household MRSA Decolonization

NCT01814371
View directory record Official record
Conditions
Staphylococcal Skin Infection, Abscess, Furunculosis, Staphylococcus Aureus, MRSA Infection
Interventions
2% mupirocin ointment, Bleach Bath (dilute), Hygiene Protocol
Drug · Other · Behavioral
Lead sponsor
Washington University School of Medicine
Other
Eligibility
Not listed
Enrollment
474 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 21, 2019 · Synced Oct 31, 2026, 3:23 PM EDT
Completed Phase 3 Interventional Results available

A Study to Compare the Safety and Efficacy of an Aromatase Inhibitor in Combination With Lapatinib, Trastuzumab or Both for the Treatment of Hormone Receptor Positive, HER2+ Metastatic Breast Cancer

NCT01160211
View directory record Official record
Conditions
Neoplasms, Breast
Interventions
Lapatinib, Trastuzumab, Aromatase Inhibitor
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older · Female only
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
4
States / cities
Hollywood, Florida • Augusta, Georgia • Germantown, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2025 · Synced Oct 31, 2026, 3:23 PM EDT
Completed Phase 2 Interventional Results available

Comparison of Rimegepant and Placebo for Pain in IBS

NCT06221111
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Rimegepant 75 MG [Nurtec]
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 31, 2026, 3:23 PM EDT
Completed Phase 2 Interventional Results available

Preoperative Bevacizumab and Trastuzumab With ABI-007 and Carboplatin in HER2+ Breast Cancer

NCT00392392
View directory record Official record
Conditions
Breast Cancer
Interventions
nab-paclitaxel, Bevacizumab, Trastuzumab
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
6
States / cities
Fort Myers, Florida • Orlando, Florida • Gainesville, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2013 · Synced Oct 31, 2026, 3:23 PM EDT
Not listed Early Phase 1 Interventional Accepts healthy volunteers

Topical Ascorbic Acid for Treatment of Squamous Cell Skin Cancer

NCT05932511
View directory record Official record
Conditions
Squamous Cell Cancer, Squamous Cell Carcinoma, Skin Cancer, Non-melanoma Skin Cancer
Interventions
30% ascorbic acid in DMSO
Drug
Lead sponsor
Center for Biomedical Research, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Boise, Idaho
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Oct 31, 2026, 3:23 PM EDT
Completed Phase 2 Interventional

PS-341 in Treating Patients With Metastatic Malignant Melanoma

NCT00024011
View directory record Official record
Conditions
Recurrent Melanoma, Stage IV Melanoma
Interventions
bortezomib, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Oct 31, 2026, 3:23 PM EDT
Completed Phase 2 Interventional

Open Label Arimidex in Gynecomastia

NCT00241436
View directory record Official record
Conditions
Gynecomastia
Interventions
Anastrozole (ARIMIDEX™)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
11 Years to 18 Years · Male only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 27, 2011 · Synced Oct 31, 2026, 3:23 PM EDT
Completed No phase listed Observational

Breast Density, Hormone Levels, and Anticancer Drug Levels in Women With Invasive Breast Cancer Who Are Receiving Exemestane or Anastrozole

NCT00316836
View directory record Official record
Conditions
Breast Cancer
Interventions
mammography
Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
554 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
311
States / cities
Fairbanks, Alaska • Scottsdale, Arizona • Fort Smith, Arkansas + 222 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2019 · Synced Oct 31, 2026, 3:23 PM EDT
Recruiting Phase 1Phase 2 Interventional

PRE-ISPY Phase I/II Oncology Platform Program

NCT05868226
View directory record Official record
Conditions
HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer, Metastatic, HER2-positive Metastatic Breast Cancer, HER2 Mutation-Related Tumors, HER-2 Protein Overexpression, HER2-negative Breast Cancer, Triple Negative Breast Cancer, HR Positive, Hormone Receptor-positive Breast Cancer, Estrogen Receptor Positive Tumor, Progesterone Receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma, Solid Tumor, Solid Tumor, Adult, Solid Carcinoma, HER2 Low Breast Cancer, HER2 Low Breast Carcinoma, ER Positive Breast Cancer, PR-positive Breast Cancer, Minimal Residual Disease, Colo-rectal Cancer, Colon Cancer, Rectal Cancer, ctDNA Monitoring, Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms, Neoplasm, Residual, Adenocarcinoma of Colon, Adenocarcinoma
Interventions
ALX148, Fam-Trastuzumab Deruxtecan-Nxki, Zanidatamab, Tucatinib, TTX-MC138
Drug
Lead sponsor
QuantumLeap Healthcare Collaborative
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
10
States / cities
Birmingham, Alabama • Phoenix, Arizona • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 31, 2026, 3:23 PM EDT
Active, not recruiting Not applicable Interventional Results available

A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)

NCT01824836
View directory record Official record
Conditions
Estrogen Receptor-positive Breast Cancer, Musculoskeletal Complications, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
anastrozole
Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older · Female only
Enrollment
1,046 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts • East Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 31, 2026, 3:23 PM EDT
Active, not recruiting Phase 2 Interventional

(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer

NCT05607004
View directory record Official record
Conditions
Breast Neoplasms, Invasive Breast Cancer, Estrogen-receptor-positive Breast Cancer, HER2-negative Breast Cancer
Interventions
(Z)-endoxifen, goserelin
Drug
Lead sponsor
Atossa Therapeutics, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
14
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 31, 2026, 3:23 PM EDT